cirtuvivint

Cirtuvivint is a first-in-class, orally administered small molecule inhibitor of CDC-like kinases (CLKs) and dual specificity tyrosine phosphorylation regulated kinases (DYRKs). It modulates alternative pre-mRNA splicing by inhibiting CLK and DYRK activity, leading to reduced expression of genes critical for tumor growth. Cirtuvivint disrupts spliceosome activity and inhibits Wnt pathway-related gene and protein expression, inducing anti-tumor effects in various cancer models. The drug is being developed primarily for oncology indications including soft tissue sarcoma, acute myeloid leukemia, myelodysplastic syndromes, non-small cell lung cancer, prostate cancer, colorectal cancer, solid tumors and other hematological malignancies. It was originally developed by Samumed and is currently under development by Biosplice Therapeutics[2][3][5][7][10].

Other names

2-(4-methylpiperazin-1-yl)-N-[6-(1-methylpyrazol-4-yl)isoquinolin-3-yl]pyridine-4-carboxamide4-pyridinecarboxamide, 2-(4-methyl-1-piperazinyl)-n-(6-(1-methyl-1h-pyrazol-4-yl)-3-isoquinolinyl)-